Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.14365/1368
Title: Genetic imaging study with [Tc-(99m)] TRODAT-1 SPECT in adolescents with ADHD using OROS-methylphenidate
Other Titles: Tc- 99m] TRODAT-1 SPECT in adolescents with ADHD using OROS-methylphenidate
Authors: Akay, Aynur Pekcanlar
Kaya, Gamze Capa
Kose, Samet
Yazicioglu, Cigdem Eresen
Erkuran, Handan Ozek
Guney, Sevay Alsen
Oguz, Kaya
Keywords: ADHD
DAT1 gene
[Tc-(99m)] TRODAT-1 SPECT
OROS-methylphenidate
Deficit Hyperactivity Disorder
Dopamine-Transporter Gene
Attention-Deficit/Hyperactivity Disorder
Tc-99m-Trodat-1 Spect
Parkinsons-Disease
Children
Association
Adults
Psychostimulants
Availability
Publisher: Pergamon-Elsevier Science Ltd
Abstract: Aim: To examine theeffects on the brain of 2-month treatment withamethylphenidate extended-release formulation (OROS-MPH) using [Tc-(99m)] TRODAT-1SPECT in a sample of treatment-naive adolescents with Attention Deficit/Hyperactivity Disorder (ADHD). In addition, to assess whether risk alleles (homozygosity for 10-repeat allele at the DAT1 gene were associated with alterations in striatal DAT availability. Methods: Twenty adolescents with ADHD underwent brain single-photon emission computed tomography (SPECT) scans with [Tc-(99m)] TRODAT-1 at baseline and two months after starting OROS-MPH treatment with dosages up to 1 mg/kg/day. Severity of illness was estimated using the Clinical Global Impression Scale (CGI-S) and DuPaul ADHD Rating Scale-Clinician version (ARS) before treatment,1 month and 2 months after initiating OROS-MPH treatment. Results: Decreased DAT availability was found in both the right caudate (pretreatment DAT binding: 224.76 +/- 33.77, post-treatment DAT binding: 208.86 +/- 28.75, p = 0.02) and right putamen (pre-treatment DAT binding: 314.41 +/- 55.24, post-treatment DAT binding: 285.66 +/- 39.20, p = 0.05) in adolescents with ADHD receiving OROS-MPH treatment. Adolescents with ADHD who showed a robust response to OROS-MPH (n = 7) had significantly greater reduction of DAT density in the right putamen than adolescents who showed less robust response to OROS-MPH (n = 13) (p = 0.02). However, between-group differences by treatment responses were not related with DAT density in the right caudate. Risk alleles (homozygosity for the 10-repeat allele of DAT1 gene) in the DAT1 gene were not associated with alterations in striatal DAT availability. Conclusion: Two months of OROS-MPH treatment decreased DAT availability in both the right caudate and putamen. Adolescents with ADHD who showed a robust response to OROS-MPH had greater reduction of DAT density in the right putamen. However,our findings did not support an association between homozygosity for a 10-repeat allele in the DAT1 gene and DAT density, assessedusing[Tc-(99m)] TRODAT-1SPECT.
URI: https://doi.org/10.1016/j.pnpbp.2018.04.008
https://hdl.handle.net/20.500.14365/1368
ISSN: 0278-5846
1878-4216
Appears in Collections:PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection
Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection

Files in This Item:
File SizeFormat 
407.pdf
  Restricted Access
559.87 kBAdobe PDFView/Open    Request a copy
Show full item record



CORE Recommender

SCOPUSTM   
Citations

7
checked on Nov 6, 2024

WEB OF SCIENCETM
Citations

6
checked on Nov 6, 2024

Page view(s)

72
checked on Nov 11, 2024

Download(s)

6
checked on Nov 11, 2024

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.